Is the Regencell (RGC) Form 3 a record of a new share purchase or sale?

No, the Form 3 records existing beneficial ownership of a stock option rather than a new market trade. It is an initial ownership statement, showing the director’s vested option over 592,230 ordinary shares at an exercise price of $0.2500.

Regencell director reports 592,230-share stock option

Regencell Bioscience Holdings Ltd director Evana Yee Wah Hui has reported her initial ownership of a stock option position in a Form 3 filing.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Regencell Bioscience Holdings Ltd director Evana Yee Wah Hui has reported her initial ownership of a stock option position in a Form 3 filing. The option gives her the right to purchase up to 592,230 ordinary shares at an exercise price of $0.2500 per share.

The option was granted on June 9, 2021 under the company’s 2021 Share Option Plan. It vested in equal portions on each of the four anniversaries of the closing of Regencell’s initial public offering and is now fully vested. The expiration date is 10 years from the dates the options became vested.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider HUI EVANA YEE WAH

Role Director

Type	Security	Shares	Price	Value
holding	Stock option (right to purchase)	--	--	--

Holdings After Transaction: Stock option (right to purchase) — 592,230 contracts (Direct)

Footnotes (1)

F1. The Reporting Person was granted the option on June 9, 2021 pursuant to the Issuer's 2021 Share Option Plan. The option vested equally each of the four anniversaries of the closing of the Issuer's initial public offering and is now fully vested. The expiration date is 10 years from the date the options become vested.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Regencell Bioscience (RGC) Form 3 filing show?

The Form 3 shows director Evana Yee Wah Hui’s initial reported ownership of a stock option. The option covers 592,230 ordinary shares at an exercise price of $0.2500 per share under the 2021 Share Option Plan and is now fully vested.

How many shares are covered by the director’s stock option in RGC?

The stock option reported covers 592,230 underlying ordinary shares. These shares are linked to a single option grant under Regencell Bioscience’s 2021 Share Option Plan and represent the director’s derivative position as disclosed in this initial ownership statement.

What is the exercise price of the Regencell (RGC) director’s stock option?

The exercise price of the director’s stock option is $0.2500 per underlying ordinary share. This means she can purchase each of the 592,230 ordinary shares at $0.2500, according to the terms of the 2021 Share Option Plan grant.

When was the Regencell (RGC) stock option granted to the director?

The option was granted on June 9, 2021 under Regencell Bioscience’s 2021 Share Option Plan. It vested in four equal parts on each anniversary of the company’s initial public offering closing and is now fully vested, according to the filing footnote.

How does the Regencell (RGC) director’s option vest and expire?

The option vested equally on each of the four anniversaries of Regencell’s initial public offering closing and is now fully vested. The filing states the expiration date is 10 years from the dates the options become vested, defining a long-dated derivative position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/18/2026 - 09:16 AM

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

HUI EVANA YEE WAH

(Last)

(First)

(Middle)

C/O 9/F CHINACHEM LEIGHTON PLAZA

29 LEIGHTON ROAD, CAUSEWAY BAY

(Street)

HONG KONG

(City)

(State)

(Zip)

CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Regencell Bioscience Holdings Ltd [ RGC ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock option (right to purchase)	⁽¹⁾	⁽¹⁾	Ordinary shares, par value $0.00001	592,230	$0.25	D

Explanation of Responses:

1. The Reporting Person was granted the option on June 9, 2021 pursuant to the Issuer's 2021 Share Option Plan. The option vested equally each of the four anniversaries of the closing of the Issuer's initial public offering and is now fully vested. The expiration date is 10 years from the date the options become vested.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ James Wai Hong Chung, attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR